European Medicines Agency

The European Medicines Agency in Amsterdam
#CAR-T #Cell therapy #European Commission #European Medicines Agency #Kite Pharma

EU relaxes safety monitoring of CAR-T therapies

The European Medicines Agency has approved a Type II variation to the Summary of Product Characteristics (SmPC) for Kite’s chimeric antigen receptor (CAR)-T cell therapies, Yescarta (axicabtagene ciloleucel) and Tecartus (brexucabtagene autoleucel). The variation includes a reduction in daily hospital safety monitoring for patients following CAR-T cell therapy infusion from… Read More

#News #Regulatory

MRI showing glioblastoma
#Brain cancer #European Medicines Agency #FDA #Oncology #Orphan drugs

Regulatory update for malignant glioma drug

Carthera, a spin-off from Sorbonne University, has been granted Orphan Drug Designation (ODD) by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the use of carboplatin in the treatment of malignant glioma. Carthera is using carboplatin in the first registrational trial of its SonoCloud… Read More

#News #Regulatory

CAR-T therapy
#CAR-T #Cell therapy #CHMP #European Medicines Agency #Myeloma #Oncology

CAR-T therapy recommended for melanoma after first relapse

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of a Type II variation for Carvykti (ciltacabtagene autoleucel; cilta-cel) for the earlier treatment of relapsed and refractory multiple myeloma (RRMM). The recommended indication for cilta-cel is for the treatment of… Read More

#News #Regulatory

#AnaMar #Autoimmune disease #European Medicines Agency #FDA #Fibrotic disease #Orphan drugs

Dual-action treatment for fibrotic disease secures orphan drug status

AM1476, a first-in-class, peripheral-acting serotonin receptor antagonist, has been granted US and EU Orphan Drug Designation as an anti-fibrotic treatment for systemic sclerosis. AM1476 is a selective peripheral-acting 5-HT2B receptor small molecule antagonist that can be delivered orally. It has demonstrated efficacy in in vitro and in vivo models of… Read More

#News #Regulatory

Brain physiology
#Clinical trials #European Medicines Agency #Neuroscience #Synendos Therapeutics

EMA approves endocannabinoid system modulator trial

Synendos Therapeutics, has received approval from the European Medicines Agency (EMA) to commence the Phase I first-in-human clinical trial of its lead asset, SYT-510, a first-in-class inhibitor that modulates a newly identified drug target in the endocannabinoid system (ECS) to restore healthy brain physiology.   The randomised, double-blind, placebo-controlled study will… Read More

#News #Regulatory

The European Medicines Agency building
#CHMP #EU #European Medicines Agency #Gene therapy #Regulatory

New drug recommendations by the EU’s CHMP

The European Medicines Agency (EMA) human medicines committee (CHMP) made a number of key recommendations at its December 2023 meeting. Casgevy The committee recommended granting a conditional marketing authorisation for Casgevy (exagamglogene autotemcel), an advanced therapy medicinal product (ATMP) for the treatment of transfusion dependent beta-thalassemia and severe sickle cell… Read More

#News #Regulatory #Trending News

#Brexit #European Commission #European Medicines Agency #MHRA #Regulatory #UK #UK budget

Two part commentary on Brexit and drug discovery

On 31 January 2020, the United Kingdom (UK) withdrew from the European Union (EU). Alongside a number of repercussions, the most impactful to the drug discovery sector arguably relates to regulatory affairs on account of adjusting from the European Medicines Agency (EMA) to the Medicines and Healthcare products Regulatory… Read More

#News

#Brexit #European Commission #European Medicines Agency #MHRA #Regulatory #UK #UK budget

Part 1: What impact has Brexit had on UK drug discovery?

On 31 January 2020, the United Kingdom (UK) withdrew from the European Union (EU). Alongside a number of repercussions, the most impactful to the drug discovery sector arguably relates to regulatory affairs on account of adjusting from the European Medicines Agency (EMA) to the Medicines and Healthcare products Regulatory Agency… Read More

#Exclusive Content #Regulatory

#Brexit #European Commission #European Medicines Agency #MHRA #Regulatory #UK #UK bidget

Part 2: What impact has Brexit had on UK drug discovery?

On 31 January 2020, the United Kingdom (UK) withdrew from the European Union (EU). Alongside a number of repercussions, the most impactful to the drug discovery sector arguably relates to regulatory affairs on account of adjusting from the European Medicines Agency (EMA) to the Medicines and Healthcare products Regulatory Agency… Read More

#Exclusive Content #Regulatory

CAR-T therapy
#CAR-T #European Commission #European Medicines Agency #Janssen #Myeloma #Oncology #Phase III trial

Janssen seeks EU approval of new indication for CAR-T therapy

The Janssen Pharmaceutical Companies of Johnson & Johnson have submitted a Type II variation application to the European Medicines Agency (EMA) seeking approval of Carvykti (ciltacabtagene autoleucel; cilta-cel) for relapsed and lenalidomide-refractory multiple myeloma. The application is supported by data from the Phase III CARTITUDE-4 study, which evaluated the safety… Read More

#News #Regulatory

EU flag
#Alliance for Regenerative Medicine #EFPIA #EU #European Commission #European Medicines Agency #Regulatory #The European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)

Proposals for changes to EU pharma legislation raise concerns for SMEs

DDW's Diana Spencer explores the European Commission's proposed changes to EU pharmaceutical legislation, the reaction from industry and possible impact on smaller companies. The European Commission (EC) has proposed the largest reform to the EU's pharmaceutical legislation in over 20 years. The EC says the revisions will make the system more agile, flexible,… Read More

#Exclusive Content #Regulatory

Male patient with doctor
#Cancer research #CHMP #European Medicines Agency #Gene mutation #Oncology #Phase III trial #Prostate cancer

Prostate cancer combination therapy reduces risk of death

The combination therapy of niraparib and abiraterone acetate (AA) could become the first dual action tablet (DAT) available in the European Union for metastatic castration-resistant prostate cancer (mCRPC) with BRCA1/2 mutations.  Janssen’s Akeega has been recommended for marketing authorisation when given with prednisone (P) or prednisolone by the Committee for… Read More

#News #Regulatory

Plaque psoriasis
#Bristol Myers Squibb #CHMP #Dermatology #European Medicines Agency #Phase III trial

First oral allosteric TYK2 inhibitor recommended in EU

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of Sotyktu (deucravacitinib) for the treatment of adults with moderate-to-severe plaque psoriasis.   Sotyktu, an oral medication taken once-daily, is a first-in-class, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment… Read More

#News #Regulatory

EMA
#AAV #Cell and gene therapy #European Medicines Agency #Forge Biologic #Gene therapy #Priority Review

EMA prioritises AAV gene therapy for Krabbe disease

The European Medicines Agency (EMA) has granted priority medicines (PRIME) designation to FBX-101, Forge Biologic’s adeno-associated virus (AAV) drug candidate for treating patients with Krabbe disease.  PRIME is a regulatory designation by the EMA that provides early and proactive support to developers of promising medicines, to advance and speed up… Read More

#News #Regulatory

Myeloma cells
#Antibody #Cancer research #Europe #European Medicines Agency #Janssen #Marketing approval authorisation #Myeloma #T-Cells

Janssen seeks European approval for multiple myeloma drug

Janssen has submitted a marketing authorisation application (MAA) seeking approval of talquetamab in Europe for the treatment of patients with relapsed or refractory multiple myeloma (RRMM).   Talquetamab is an investigational, off-the-shelf, bispecific T-cell engager antibody targeting both GPRC5D, a novel drug target that is on some normal… Read More

#Cancer Research #News

Map of Europe
#CNS #Collaboration #European Medicines Agency #License agreement #Orphan drugs

Alliance will provide a new therapy for rare CNS disease 

Minoryx and Neuraxpharm have agreed a strategic alliance to provide a new therapy for rare CNS disease patients in Europe.  The companies have entered into a license agreement for the European rights to leriglitazone, currently under European Medicines Agency (EMA) review for the orphan indication X-linked Adrenoleukodystrophy… Read More

#News